Please assess the completion status of the following clinical trial:

Trial Title: Standard Process Heart and Gut Health Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy participants (both male and female) aged 25-80 years with omnivorous diet (regular consumption of eggs, red meat, dairy)~* No pre or probiotic consumption during study, no antibiotics during study~* Moderate to high serum levels of TMAO (more than or equal to 4 uM) determined by a standard blood test~* If the participant is on antibiotics, they should finish their medication and wait one month before testing for TMAO as a screening criterion~* Normal blood pressure, non-smokers~* Normal cholesterol~* Participants can communicate and follow instructions~* Participants voluntarily signed and dated an informed consent (ICF), reviewed by an Institutional Review Board (IRB), and provided authorization prior to any participation in the study~* Participants who are willing to take nutritional supplements and have no known food allergies~Exclusion Criteria:~* Vegan and vegetarian participants~* Participants on medically prescribed diet~* Participants not willing to stop consumption of fermented products (plain yogurt, kefir, kombucha, water kefir, miso, pickled vegetables, and sauerkraut) 2 weeks prior to the study start date and during the study timeline as this will interfere with gut microbiome related outcome assessment~* Participants not willing to stop consuming polyphenols- green tea, cocoa, flaxseed, berries, and energy drinks~* Participants who are currently or have participated in other interventional clinical trials in the last 4 weeks~* Participants on certain supplements like GI health related (Probiotics, prebiotics, and/or antimicrobial botanicals), vitamin C, Choline, lecithin or L-carnitine, fish oil/krill oil containing supplements who don't wish to stop supplementation prior to 2 weeks of study start date~* Participants who have any confirmed or suspected infectious disease (such as tuberculosis, Hepatitis B or C, HIV infection), malignancy, or any other clinically significant medical condition, which in the investigators' opinion, makes him or her not suitable for inclusion in the study\*~* Participants who have pacemakers, an implanted cardioverter defibrillator (ICD), or a cardiac resynchronization therapy device~* Participants who have confirmed or suspected pregnancy (self-reported)~* Participant waiting for a heart transplant~* Participants currently hospitalized for acute myocardial infarction~* Participants with a planned revascularization within 30 days of screening~* Participants must not have any allergies to supplement ingredients (see list)~* Participants who have initiated the use of prescription medications (defined as a medication that can be prescribed only by a properly authorized/licensed clinician), and not authorized non-prescription medications (over-the-counter medications), and other nutritional supplements~* Participants who do not comply with all study requirements (including clinical visits)~* Participants with high cholesterol or on lipid lowering medications like statins~* Participants on following medication: NSAIDS, Steroids, Prednisone, Acid Reflux/GERD medicines: Tagamet, Zantac, Pepcid, Prilosec, Prevacid

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Diet Only Group (Type: NO_INTERVENTION): Diet only: guided diet
- Combination Group (Type: EXPERIMENTAL): Combination of whole food-based B and D vitamins
- B Only Group (Type: EXPERIMENTAL): Whole food-based B vitamins

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues